COSTEM 2022 | The future of CAR-T therapy in the management of DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, comments on the current role of CAR-T therapy in the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Whilst autologous stem cell transplantation (ASCT) has been the standard of care, multiple trials including the ZUMA-7 (NCT03391466) and TRANSFORM trials (NCT03575351) assessing axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) respectively have put CAR-Ts on the forefront of DLBCL treatment. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
